II. Epidemiology
- Age: Children ages 1 to 10 years old most commonly affected
- Contrast with Thrombotic Thrombocytopenic Purpura which is seen primarily in adults
- Incidence: 1-3 per 100,000
- Peak timing: June to September in United States
III. Pathophysiology
- Shiga-Toxin Producing Escherichia coli in 90% of cases (e.g. 0157:H7, STEC)
- See Diarrhea-positive Hemolytic Uremic Syndrome below
- Other uncommon causes include Shigella dysenteriae, Streptococcus Pneumoniae, HIV Infection, and Influenza
- Proinflammatory factors (IL-8, TNFa)
- Prothombotic Changes
- Fibrin deposited in renal microvasculature
- Verocytotoxin induces endothelial injury
- Red Blood Cell destruction
- Platelet destruction, consumption, sequestration
- Platelet thrombus formation
- Classic triad (follows Abdominal Pain and Diarrhea)
- Predictors of HUS development (3-15% of STEC Diarrhea)
- Very young or elderly
- Close contact with farm animals
- Bloody Diarrhea
- Fever
- Increased White Blood Cell Count
- Increased C-Reactive Protein
- Early use of Antibiotics in STEC Diarrhea
- Results in prolonged intestinal exposure to toxin
IV. Types
-
Diarrhea-positive Hemolytic Uremic Syndrome
- Related to Shiga-toxin producing Escherichia coli
-
Diarrhea-negative Hemolytic Uremic Syndrome
- Sporadic in adults
- Consider Thrombotic Thrombocytopenic Purpura
V. Risk Factors
- Familial risk (Factor H Deficiency)
- Precipitating Infection
- Predisposing Medications
- Predisposing Conditions
- Pregnancy
- Systemic Lupus Erythematosus
- Glomerulonephritis
- Cancer
-
Escherichia coli 0157:H7 (Shiga-Toxin) exposures
- Vegetables: Alfalfa/radish sprouts, leaf lettuce
- Undercooked Meats: Deer, Ground beef, sausage, deli
- Unpasteurized drinks: Apple juice, Milks
- Contaminated lakes or municipal water supplies
- Petting farm animals
VI. Symptoms (symptomatic in all children)
- Follows 3-4 day Incubation Period of E. coli 0157:H7
-
Diarrhea
- Bloody Diarrhea (precedes HUS by 3-14 days)
- Non-bloody in some cases
- Abdominal cramping
- Nausea or Vomiting
- Low-grade fever
-
Petechiae and Purpura are rarely present
- Contrast with Thrombotic Thrombocytopenic Purpura
VII. Diagnosis
VIII. Labs
-
Complete Blood Count with Platelets
- Anemia with Hemoglobin 8-9 g/dl due to Hemolysis
- Thromboctopenia (Platelet Count <150,000)
- Leukocytosis
-
Peripheral Smear
- Hemolysis (Burr cells, helmet cells)
-
Stool Culture
- Escherichia coli 0157:H7 variably positive
- May have resolved by the time HUS presents
-
Renal Function Tests
- Blood Urea Nitrogen increased
- Serum Creatinine increased
- Urinalysis
- Other findings
- Increased Lactate Dehydrogenase
- Coombs negative
- Reticulocyte Count increased
- Decreased Haptoglobin
IX. Differential Diagnosis
-
Thrombotic Thrombocytopenic Purpura
- Occurs more often in adults
- Neurologic sequelae more common than renal
- Bloody Diarrhea typically absent
- Appendicitis
- Inflammatory Bowel Disease
- Intussusception
- Systemic Lupus Erythematosus
- Disseminated Intravascular Coagulation
- Acute Gastroenteritis
X. Management
- Despite similarity to TTP, treatment is different
- Supportive Care
- Fluid and Electrolyte management
- Hydration prior to HUS decreases Renal Failure
- Monitor Hemoglobin, Hematocrit and Platelets
- Transfuse Red Blood Cells to keep Hemoglobin >6-7
- Platelet Transfusions are controversial
- May risk thrombosis
- Hemodialysis if Renal Failure occurs
- Fluid and Electrolyte management
- Ineffective or proovcative treatments to avoid
- Antibiotics are to be avoided
- Worsen complication rate
- Increase risk of HUS in STEC Diarrhea
- Plasmaphoresis
- Anti-thrombotic agents
- Corticosteroids
- Shiga toxin-binding agents
- Antibiotics are to be avoided
XI. Complications
- Gastrointestinal complications
- Rectal Prolapse and colitis (10% of cases)
- Intussusception
- Pancreatitis
- Intestinal perforation
- Neurologic complications (10%, higher mortality risk)
- Renal complications
- Chronic Renal Failure (25% risk, 3% risk of ESRD)
- Hypertension
XII. Prognosis
- Hospital stay: 11 days on average
- Survival: 90-95%
XIII. References
- Merrill and Gillen (2016) Crit Dec Emerg Med 30(3): 3-8
- Baker (2000) Curr Opin Pediatr 12(1):23-8 [PubMed]
- Kakishita (2000) Int J Hematol 71(4):320-7 [PubMed]
- Razzaq (2006) Am Fam Physician 74:991-8 [PubMed]
- Robson (2000) Paediatr Drugs 2(4):243-52 [PubMed]
- Thorpe (2004) Clin Infect Dis 38:1298-303 [PubMed]
- Trachtman (1999) Curr Opin Pediatr 11(2):162-8 [PubMed]